ReviewDigestive diseases and sciences2017
Furazolidone, an Underutilized Drug for H. pylori Eradication: Lessons from Iran.
Review in Digestive diseases and sciences, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.
- Safety of furazolidone-containing regimen inBMJ open · 2020Pooled it
- The Association betweenGenes · 2020Trial
- Efficacies of different proton pump inhibitor-based 14-day bismuth-furazolidone quadruple regimens for the initial eradication of Helicobacter pylori in the southeast coastal region of China: an open-label, randomized clinical trial.Clinical and experimental medicine · 2018Trial
- Efficacy and Safety of Modified Bismuth Quadruple Therapy for First-LineMicroorganisms · 2025Review
- Review
- Exploring Alternative Treatment Choices for Multidrug-Resistant Clinical Strains ofMicroorganisms · 2023Article
- Newer, Older, and Alternative Agents for the Eradication ofAntibiotics (Basel, Switzerland) · 2023Review
- Antibiotic resistance in Helicobacter pylori: From potential biomolecular mechanisms to clinical practice.Journal of clinical laboratory analysis · 2023Review
- Late-stage functionalization of 5-nitrofurans derivatives and their antibacterial activities.RSC advances · 2023Article
- Implications of the paradigm shift in management ofTherapeutic advances in gastroenterology · 2023Review
- Clinical Factors Implicated in Antibiotic Resistance inMicroorganisms · 2022Review
- The efficacy and safety of furazolidone-bismuth quadruple therapy forGastroenterology and hepatology from bed to bench · 2022Article
- Risk factors of furazolidone-associated fever.PloS one · 2022Article
- Helicobacter pylori infection and antibiotic resistance - from biology to clinical implications.Nature reviews. Gastroenterology & hepatology · 2021Review
- Comparing the Effect of Two Low-dose and High-dose Four-drug Regimens of Furazolidone in EradicatingMiddle East journal of digestive diseases · 2021Article
- Review
- Cost-effectiveness analysis of two routine therapeutic methods forGastroenterology and hepatology from bed to bench · 2021Article
- Two-weeks repeated-dose oral toxicity study of Pediococcus acidilactici J9 in a mice model.BMC microbiology · 2020Article
- Rifabutin and Furazolidone Could Be the Candidates of the Rescue Regimen for Antibiotic-ResistantThe Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2019Article
- Effective therapeutic regimens in two South Asian countries with high resistance to majorAntimicrobial resistance and infection control · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 2 countries.
Funding
Abstract
backgroundTreatment success of H. pylori eradication therapy has declined worldwide largely because of increased antimicrobial resistance. New therapeutic approaches are needed, especially for countries like Iran, where resistance to commonly used drugs is already widespread and traditional H. pylori therapies produce poor cure rates.
aimTo review the results of quadruple therapy trials containing bismuth and furazolidone in Iran.
methodsWe searched PubMed, Google scholar as well as the references of all published papers for studies conducted in Iran, utilizing furazolidone in the treatment of H. pylori infections. The target population was four drug studies that utilized a combination of bismuth, furazolidone, amoxicillin, or tetracycline plus a proton pump inhibitor.
resultsEighteen studies with 22 arms including 1713 subjects were found. The weighted mean cure rate for 14-day studies (six studies) using 200 mg b.i.d. furazolidone was 80% intention to treat (ITT) and 87% per protocol (PP). Studies using 100 mg b.i.d. (three studies) were less effective (weighted mean ITT cure rate = 67%). One small 14-day study with furazolidone 100 mg q.i.d. achieved cure rates of 94.5% ITT and PP.
conclusionsAlthough furazolidone-bismuth quadruple therapy proved relatively effective in Iran, furazolidone-containing regimens remain to be optimized. Based on these data and results from China, it appears likely that 14-day therapy containing furazolidone 100 mg t.i.d. or q.i.d. is likely to provide the highest cure rates with lowest side effects; this remains to be experimentally tested. Detailed suggestions for further development of furazolidone-containing regimens are provided.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.